Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mDR18
- Development stage
- Preclinical
- Lead developer
- Northeastern University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral, Intravenous
01
Overview
mDR18 is an engineered murine decoy-resistant interleukin-18 (IL18) mutein delivered via a live bacterial platform. It is specifically designed to evade the inhibitory effects of the IL18 binding protein (IL18BP), which normally acts as a secreted immune checkpoint by neutralizing IL18. In this therapeutic system, mDR18 is expressed on the outer membrane of non-pathogenic *Escherichia coli* K-12 DH5α using bacterial scaffolds such as OmpA. This surface-display approach is intended to enhance the cytokine's effective concentration and half-life within the tumor microenvironment (TME) through surface anchoring and clustering. Preclinical studies demonstrate that mDR18-displaying bacteria induce robust CD8+ T cell and natural killer (NK) cell-dependent anti-tumor immune responses, promote immunologic memory, and exhibit abscopal effects in colorectal carcinoma and melanoma models.
- Other names
- murine decoy-resistant IL18 muteinmurine interleukin-18-CS2DR18DR-18DR 18
02
Targets
IL-18R (Interleukin-18 receptor complex)
Beyond the preview
Go deeper on mDR18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mDR18.